Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JONATHAN ASIF ABBAS

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1316145253
CMS profile
241356
Location
NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$234,631.39

259 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 5 of 6; records 201–250 of 259 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JONATHAN ASIF ABBAS

NPI 1316145253 · CMS profile ID 241356

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 6; records 201–250 of 259 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1316145253?year=2023&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JONATHAN ASIF ABBAS, NPI 1316145253, CMS profile ID 241356. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 259 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316145253?year=2023&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JONATHAN ASIF ABBAS, NPI 1316145253, CMS profile ID 241356. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 259 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316145253?year=2023&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JONATHAN ASIF ABBAS, NPI 1316145253, CMS profile ID 241356, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 6; records 201–250 of 259 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1316145253?year=2023&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

259 matching records · $234,631.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 259 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 259.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Pharmacyclics LLC, An AbbVie Company $124.0503/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998280537 CMS
Pharmacyclics LLC, An AbbVie Company $719.9603/30/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998280539 CMS
SERVIER PHARMACEUTICALS LLC $280.0003/30/2023 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055089499 CMS
Incyte Corporation $21.4003/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044501905 CMS
Incyte Corporation $242.5003/28/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044502725 CMS
Roche Diagnostics Corporation $57.9803/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059018773 CMS
Roche Diagnostics Corporation $86.5303/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059018777 CMS
Incyte Corporation $1.2503/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044501913 CMS
Incyte Corporation $1.2503/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044501923 CMS
AbbVie Inc. $123.4703/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996075301 CMS
AbbVie Inc. $23.2503/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996075303 CMS
Celgene Corporation $767.9603/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016072535 CMS
Celgene Corporation $164.8803/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016072771 CMS
E.R. Squibb & Sons, L.L.C. $6,479.0003/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016072563 CMS
JAZZ PHARMACEUTICALS INC. $4,340.0003/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058402113 CMS
Karyopharm Therapeutics Inc. $48.8403/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056903023 CMS
Genmab U.S., Inc. $116.1403/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051345523 CMS
Novartis Pharmaceuticals Corporation $24.7903/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991854149 CMS
E.R. Squibb & Sons, L.L.C. $115.9103/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016072565 CMS
AstraZeneca Pharmaceuticals LP $123.2603/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016017115 CMS
Gilead Sciences, Inc. $22.7303/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025716827 CMS
Incyte Corporation $4,850.0003/07/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044501864 CMS
Incyte Corporation $50.0003/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044501827 CMS
Incyte Corporation $25.0803/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044501837 CMS
Incyte Corporation $26.0603/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044501853 CMS
Incyte Corporation $98.8603/01/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044501875 CMS
AbbVie Inc. $1,500.0002/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996075299 CMS
Pharmacyclics LLC, An AbbVie Company $3,100.0002/24/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998280535 CMS
E.R. Squibb & Sons, L.L.C. $5,929.0002/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016072555 CMS
E.R. Squibb & Sons, L.L.C. $183.4002/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016072559 CMS
SERVIER PHARMACEUTICALS LLC $1,260.0002/23/2023 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055089505 CMS
GENZYME CORPORATION $2,114.0002/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050119025 CMS
GENZYME CORPORATION $92.5502/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050119029 CMS
Regeneron Healthcare Solutions, Inc. $29.4902/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999064955 CMS
Incyte Corporation $125.0002/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044501843 CMS
Incyte Corporation $706.9602/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044501885 CMS
Celgene Corporation $60.5902/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016072527 CMS
CTI BioPharma Corp. $15.6002/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1039692005 CMS
E.R. Squibb & Sons, L.L.C. $99.6002/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016072551 CMS
JAZZ PHARMACEUTICALS INC. $279.6102/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058400765 CMS
JAZZ PHARMACEUTICALS INC. $78.8202/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058400797 CMS
JAZZ PHARMACEUTICALS INC. $400.8502/06/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058400817 CMS
JAZZ PHARMACEUTICALS INC. $35.0002/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058400893 CMS
Janssen Biotech, Inc. $550.0002/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988366043 CMS
AbbVie Inc. $1,500.0001/30/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996075297 CMS
JAZZ PHARMACEUTICALS INC. $6,820.0001/30/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058400911 CMS
Pharmacyclics LLC, An AbbVie Company $95.6301/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998280533 CMS
GENZYME CORPORATION $21.8101/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050119009 CMS
Puma Biotechnology, Inc. $14.6801/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059051439 CMS
JAZZ PHARMACEUTICALS INC. $4,340.0001/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1058400717 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $140,923.18 188
PY2020 $96,913.05 98
PY2021 $165,597.46 163
PY2022 $304,032.12 320
PY2023 $234,631.39 259
PY2024 $191,036.81 192
PY2025 $176,174.14 212

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $252,434.17 50
PY2024 Recipient $896.11 1
PY2023 Recipient $3,343.24 1
PY2022 Recipient $2,995.47 1
PY2021 Recipient $495.09 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

50 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Stemline Therapeutics Inc. $1,000.00 12/24/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135173
Principal investigator 1 Stemline Therapeutics Inc. $250.00 12/24/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135214
Principal investigator 1 AstraZeneca Pharmaceuticals LP $55,800.00 12/12/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Modular Phase I II Open Label Multi Centre Study to Evaluate the Safety Tolerability Pharmacokinetics Immunogenicity and Preliminary Efficacy of AZD4512 Monotherapy or in Combination with Anticancer Agents in Participants with Acute Lymphoblastic Leukemia No dispute reported 06/30/2026 1185554787
Principal investigator 1 Stemline Therapeutics Inc. $1,000.00 12/12/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135189
Principal investigator 1 Stemline Therapeutics Inc. $250.00 12/12/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135220
Principal investigator 1 Stemline Therapeutics Inc. $1,250.00 12/12/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135231
Principal investigator 1 Stemline Therapeutics Inc. $1,250.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135160
Principal investigator 1 Stemline Therapeutics Inc. $1,000.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135165
Principal investigator 1 Stemline Therapeutics Inc. $1,750.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135168
Principal investigator 1 Stemline Therapeutics Inc. $2,500.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135177
Principal investigator 1 Stemline Therapeutics Inc. $250.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135179
Principal investigator 1 Stemline Therapeutics Inc. $14,000.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135184
Principal investigator 1 Stemline Therapeutics Inc. $1,000.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135193
Principal investigator 1 Stemline Therapeutics Inc. $1,500.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135197
Principal investigator 1 Stemline Therapeutics Inc. $2,500.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135202
Principal investigator 1 Stemline Therapeutics Inc. $1,750.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135205
Principal investigator 1 Stemline Therapeutics Inc. $1,500.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135210
Principal investigator 1 Stemline Therapeutics Inc. $5,800.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135217
Principal investigator 1 Stemline Therapeutics Inc. $750.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135224
Principal investigator 1 Stemline Therapeutics Inc. $23,500.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135228
Principal investigator 1 Stemline Therapeutics Inc. $1,000.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135235
Principal investigator 1 Stemline Therapeutics Inc. $4,000.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135240
Principal investigator 1 GlaxoSmithKline, LLC. $2,505.60 11/07/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192158938
Principal investigator 1 GlaxoSmithKline, LLC. $5,821.20 10/29/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192154359
Principal investigator 1 GlaxoSmithKline, LLC. $2,505.60 10/16/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192158969
Principal investigator 1 GlaxoSmithKline, LLC. $3,720.60 09/23/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192154344
Principal investigator 1 GlaxoSmithKline, LLC. $3,315.60 09/18/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192158934
Principal investigator 1 GlaxoSmithKline, LLC. $3,315.60 09/12/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192158956
Principal investigator 1 GlaxoSmithKline, LLC. $6,766.20 08/21/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192161198
Principal investigator 1 GlaxoSmithKline, LLC. $3,450.60 08/14/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192158964
Principal investigator 1 GlaxoSmithKline, LLC. $6,901.20 08/07/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192161189
Principal investigator 1 GlaxoSmithKline, LLC. $3,315.60 07/31/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192161201
Principal investigator 1 GlaxoSmithKline, LLC. $9,655.88 07/10/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192158952
Principal investigator 1 Stemline Therapeutics Inc. $20.90 07/08/2025 Non-covered Recipient Entity
TENNESSEE ONCOLOGY - CHATTANOOGA - MEMORIAL PLAZA
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135128
Principal investigator 1 GlaxoSmithKline, LLC. $6,340.28 07/04/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192158942
Principal investigator 1 Stemline Therapeutics Inc. $46.60 06/26/2025 Non-covered Recipient Entity
TENNESSEE ONCOLOGY - CHATTANOOGA - MEMORIAL PLAZA
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135108
Principal investigator 1 Stemline Therapeutics Inc. $237.62 06/26/2025 Non-covered Recipient Entity
TENNESSEE ONCOLOGY - CHATTANOOGA - MEMORIAL PLAZA
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135116
Principal investigator 1 Stemline Therapeutics Inc. $85.99 06/20/2025 Non-covered Recipient Entity
TENNESSEE ONCOLOGY - CHATTANOOGA - MEMORIAL PLAZA
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135099
Principal investigator 1 Stemline Therapeutics Inc. $4,200.00 06/20/2025 Non-covered Recipient Entity
TENNESSEE ONCOLOGY - CHATTANOOGA - MEMORIAL PLAZA
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135103
Principal investigator 1 Stemline Therapeutics Inc. $10.60 06/20/2025 Non-covered Recipient Entity
TENNESSEE ONCOLOGY - CHATTANOOGA - MEMORIAL PLAZA
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135112
Principal investigator 1 Stemline Therapeutics Inc. $165.00 06/20/2025 Non-covered Recipient Entity
TENNESSEE ONCOLOGY - CHATTANOOGA - MEMORIAL PLAZA
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135120
Principal investigator 1 Stemline Therapeutics Inc. $175.82 06/20/2025 Non-covered Recipient Entity
TENNESSEE ONCOLOGY - CHATTANOOGA - MEMORIAL PLAZA
STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY No dispute reported 06/30/2026 1244135123
Principal investigator 1 GlaxoSmithKline, LLC. $3,720.60 06/19/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192158948
Principal investigator 1 GlaxoSmithKline, LLC. $3,315.60 05/28/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192154354
Principal investigator 1 GlaxoSmithKline, LLC. $6,901.20 05/08/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192154349
Principal investigator 1 GlaxoSmithKline, LLC. $12,000.00 04/10/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192154339
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 04/10/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192158960
Principal investigator 1 GlaxoSmithKline, LLC. $3,250.00 04/10/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192161194
Principal investigator 1 GlaxoSmithKline, LLC. $28,250.00 04/01/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192161209
Principal investigator 1 GlaxoSmithKline, LLC. $6,340.28 03/19/2025 Non-covered Recipient Entity
ONEONCOLOGY RESEARCH NETWORK LLC
A PHASE 2 OPEN-LABEL STUDY TO EVALUATE MOMELOTINIB IN COMBINATION WITH No dispute reported 06/30/2026 1192161204